A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Study Summary

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.

Conditions

Esophageal Squamous Cell Carcinoma

Interventions / Drugs

Paclitaxel Irinotecan Pembrolizumab MK-4830 Lenvatinib Sacituzumab tirumotecan Antihistamine H2 Receptor Antagonist Acetaminophen (or equivalent)Dexamethasone (or equivalent)Steroid Mouthwash (dexamethasone or equivalent)Supportive care measures

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment230 participants

Primary Completion—

Lead SponsorMerck Sharp & Dohme LLC

Data Retrieved2026-04-11 02:55:36.206420+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.